Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.

The drug will be sold under the brand Rezlidhia and indicated for treating acute myeloid leukemia in patients with a susceptible genetic mutation.

On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.